MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial.

ABSTRACT:

Background and purpose

Treatments to facilitate recovery after traumatic brain injury (TBI) are urgently needed. We conducted a 9-month pilot, randomized placebo-controlled clinical trial to examine the safety and potential effects of the herbal supplement MLC901 (NeuroAiD II™) on cognitive functioning following TBI.

Methods

Adults aged 18-65 years at 1-12 months after mild or moderate TBI were randomized to receive MLC901 (0.8 g capsules 3 times daily) or placebo for 6 months. The primary outcome was cognitive functioning as assessed by the CNS Vital Signs online neuropsychological test. Secondary outcomes included the Cognitive Failures Questionnaire, the Rivermead Post-concussion Symptom Questionnaire (neurobehavioral sequelae), Quality of Life after Brain Injury, Hospita

SUBMITTER: Theadom A 

PROVIDER: S-EPMC6055867 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature